We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 58

IP in the digital age: a tricky path ahead for pharma companies?
  • Hogan Lovells
  • European Union
  • September 19 2016

The pharmaceutical industry is becoming increasingly interested in digital health and serious money is being invested in the technology


Court rules that proteins produced through different methods are same product under SPC regulation
  • Hogan Lovells
  • European Union, France
  • August 15 2016

On January 18 2007 the US government filed supplementary protection certificate (SPC) application 08C0003 in regard to a European patent for


Italy: Teva vs. Novartis - Paediatric extensions of SPCs valid following removal of orphan designation
  • Hogan Lovells
  • European Union, Italy
  • July 19 2016

By order issued on February 26th, 2016 and only recently made available in a public database, the Court of Milan declared the validity of the


Brexit First Aid for Pharma
  • Hogan Lovells
  • European Union, United Kingdom
  • May 24 2016

Should the UK choose to leave the EU, there will be a substantial impact for the UK pharmaceutical industry. Crucially, these implications will not


The Hague Court confirms paediatric extension of SPC for former EU orphan drug imatinib
  • Hogan Lovells
  • European Union
  • April 6 2016

In the EU, several different rewards and incentives apply for conducting clinical trials in the paediatric population. Supplementary Protection


CJEU judgment on Merck Canada Inc. & Merck Sharp & Dohme Ltd v Sigma Pharmaceuticals plc, case C-53913, 12 February 2015
  • Hogan Lovells
  • European Union
  • February 16 2015

The CJEU has recently clarified when patent and SPC rights can be relied on under the Specific Mechanism to prevent parallel imports within the EU


EU, UK: CJEU opinion delivered on the Specific Mechanism
  • Hogan Lovells
  • European Union, United Kingdom
  • October 23 2014

Advocate General Niilo Jääskinen’s opinion on the interpretation of the Specific Mechanism (in the case of Merck v Sigma (Case C-53913) was


English court asks the CJEU to try again on supplementary protection certificates
  • Hogan Lovells
  • European Union, United Kingdom
  • October 25 2012

Following two recent decisions of the English High Court, preliminary references have been made to the European Court of Justice seeking clarity on when a supplementary protection certificate can be granted for pharmaceutical products comprising combinations of active ingredients


EPO patent examination guidelines to reflect stem cells ruling
  • Hogan Lovells
  • European Union
  • July 20 2012

The European Patent Office (EPO)'s latest revisions to the Guidelines for Examination (in force on 20 June 2012) now reflect the Brüstle ruling of the Court of Justice (CJEU) on the patentability of stem cell inventions using human embryos


CJEU confirms the availability of negative term Supplementary Protection Certificates ("SPCs") in Januvia case
  • Hogan Lovells
  • European Union
  • December 8 2011

The Court of Justice of the European Union (CJEU) gave its decision in the Januvia case today, 8 December 2011